BRPI0411221A - composto, medicamento, métodos para inibir a produção de citocinas inflamatórias, e para a prevenção ou tratamento de doenças associadas com citocinas inflamatórias, método para o tratamento ou alìvio de febre, dor e/ou inflamação e, métodos para a prevenção ou tratamento de artrite reumatóide, de osteoartrite, de doença septicêmica, psorìase, doença de crohn, colite ulcerativa, diabete melito ou, hepatite - Google Patents

composto, medicamento, métodos para inibir a produção de citocinas inflamatórias, e para a prevenção ou tratamento de doenças associadas com citocinas inflamatórias, método para o tratamento ou alìvio de febre, dor e/ou inflamação e, métodos para a prevenção ou tratamento de artrite reumatóide, de osteoartrite, de doença septicêmica, psorìase, doença de crohn, colite ulcerativa, diabete melito ou, hepatite

Info

Publication number
BRPI0411221A
BRPI0411221A BRPI0411221-0A BRPI0411221A BRPI0411221A BR PI0411221 A BRPI0411221 A BR PI0411221A BR PI0411221 A BRPI0411221 A BR PI0411221A BR PI0411221 A BRPI0411221 A BR PI0411221A
Authority
BR
Brazil
Prior art keywords
treatment
prevention
disease
methods
inflammatory cytokines
Prior art date
Application number
BRPI0411221-0A
Other languages
English (en)
Inventor
Tomio Kimura
Nobuyuki Ohkawa
Akira Nakao
Takayoshi Nagasaki
Takaichi Shimozato
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BRPI0411221A publication Critical patent/BRPI0411221A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

"COMPOSTO, MEDICAMENTO, MéTODOS PARA INIBIR A PRODUçãO DE CITOCINAS INFLAMATóRIAS, E PARA A PREVENçãO OU TRATAMENTO DE DOENçAS ASSOCIADAS COM CITOCINAS INFLAMATóRIAS, MéTODO PARA O TRATAMENTO OU ALìVIO DE FEBRE, DOR E/OU INFLAMAçãO, E, MéTODOS PARA A PREVENçãO OU TRATAMENTO DE ARTRITE REUMATóIDE, DE OSTEOARTRITE, DE DOENçA SEPTICêMICA, PSORìASE, DOENçA DE CROHN, COLITE ULCERATIVA, DIABETE MELITO OU, HEPATITE". Um composto de amina terciária cíclica que é capaz de inibir a produção de citocina inflamatória. Este é um composto que tem uma estrutura representada pela seguinte fórmula geral (I): (em que A representa um grupo trivalente opcionalmente substituído derivado de pirimidina, pirrol ou coisa parecida; R¬ 1¬ representa arila ou heteroarila opcionalmente substituidas; R¬ 2¬ representa heteroarila opcionalmente substituída; e R¬ 3¬ representa amino terciário cíclico) ou um sal farmacologicamente aceitável do composto.
BRPI0411221-0A 2003-06-11 2004-06-10 composto, medicamento, métodos para inibir a produção de citocinas inflamatórias, e para a prevenção ou tratamento de doenças associadas com citocinas inflamatórias, método para o tratamento ou alìvio de febre, dor e/ou inflamação e, métodos para a prevenção ou tratamento de artrite reumatóide, de osteoartrite, de doença septicêmica, psorìase, doença de crohn, colite ulcerativa, diabete melito ou, hepatite BRPI0411221A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003165991 2003-06-11
PCT/JP2004/008492 WO2004111037A1 (ja) 2003-06-11 2004-06-10 環状3級アミン化合物

Publications (1)

Publication Number Publication Date
BRPI0411221A true BRPI0411221A (pt) 2006-07-18

Family

ID=33549242

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411221-0A BRPI0411221A (pt) 2003-06-11 2004-06-10 composto, medicamento, métodos para inibir a produção de citocinas inflamatórias, e para a prevenção ou tratamento de doenças associadas com citocinas inflamatórias, método para o tratamento ou alìvio de febre, dor e/ou inflamação e, métodos para a prevenção ou tratamento de artrite reumatóide, de osteoartrite, de doença septicêmica, psorìase, doença de crohn, colite ulcerativa, diabete melito ou, hepatite

Country Status (14)

Country Link
US (1) US20070049620A1 (pt)
EP (1) EP1632488A1 (pt)
KR (1) KR20060017865A (pt)
CN (1) CN1863793A (pt)
AU (1) AU2004247560B2 (pt)
BR (1) BRPI0411221A (pt)
CA (1) CA2528929A1 (pt)
IL (1) IL172338A0 (pt)
MX (1) MXPA05013584A (pt)
NO (1) NO20060142L (pt)
RU (1) RU2006100301A (pt)
TW (1) TW200508215A (pt)
WO (1) WO2004111037A1 (pt)
ZA (1) ZA200510040B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050159444A1 (en) * 2002-07-19 2005-07-21 Sankyo Company, Limited Bicyclic unsaturated tertiary amine compounds
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
US8114532B2 (en) * 2007-01-26 2012-02-14 Konica Minolta Holdings, Inc. Organic electroluminescent element, display device and lighting device
US20090054392A1 (en) * 2007-08-20 2009-02-26 Wyeth Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
MX336268B (es) 2011-07-29 2016-01-13 Toyama Chemical Co Ltd Compuesto de amidina o sal del mismo.
WO2014145873A2 (en) 2013-03-15 2014-09-18 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
CA3112326A1 (en) 2018-09-12 2020-03-19 Novartis Ag Antiviral pyridopyrazinedione compounds
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
CA3121202A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
KR20250127350A (ko) 2019-09-26 2025-08-26 노파르티스 아게 항바이러스성 피라졸로피리디논 화합물
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122666B2 (en) * 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
WO2001034149A1 (en) * 1999-11-12 2001-05-17 Merck & Co., Inc. Diaryl piperidyl pyrrole derivatives as antiprotozoal agents
AU1596101A (en) * 1999-11-12 2001-06-06 Merck & Co., Inc. Aliphatic amine substituted piperidyl diaryl pyrrole derivatives as antiprotozoal agents
WO2001034632A2 (en) * 1999-11-12 2001-05-17 Merck & Co., Inc. Aliphatic hydroxy substituted piperidyl diaryl pyrrole derivatives as antiprotozoal agents
ATE377598T1 (de) * 2001-01-22 2007-11-15 Sankyo Co Durch bicyclische aminogruppen substituierte verbindungen
US20050159444A1 (en) * 2002-07-19 2005-07-21 Sankyo Company, Limited Bicyclic unsaturated tertiary amine compounds

Also Published As

Publication number Publication date
IL172338A0 (en) 2009-02-11
RU2006100301A (ru) 2006-07-10
ZA200510040B (en) 2006-09-27
KR20060017865A (ko) 2006-02-27
NO20060142L (no) 2006-03-09
CA2528929A1 (en) 2004-12-23
US20070049620A1 (en) 2007-03-01
MXPA05013584A (es) 2006-03-09
EP1632488A1 (en) 2006-03-08
AU2004247560B2 (en) 2007-11-29
CN1863793A (zh) 2006-11-15
AU2004247560A1 (en) 2004-12-23
WO2004111037A1 (ja) 2004-12-23
TW200508215A (en) 2005-03-01

Similar Documents

Publication Publication Date Title
BRPI0411221A (pt) composto, medicamento, métodos para inibir a produção de citocinas inflamatórias, e para a prevenção ou tratamento de doenças associadas com citocinas inflamatórias, método para o tratamento ou alìvio de febre, dor e/ou inflamação e, métodos para a prevenção ou tratamento de artrite reumatóide, de osteoartrite, de doença septicêmica, psorìase, doença de crohn, colite ulcerativa, diabete melito ou, hepatite
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
CR20210602A (es) Compuestos de pirrolidina
BRPI0407810A (pt) composto, composição farmacêutica, ativador da glicocinase, e, medicamento
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
BRPI0507984A (pt) composto ou um sal do mesmo, processo para produzir um composto, medicamento, métodos para antagonizar angiotensina ii em um mamìfero, para melhorar a resistência de insulina em um mamìfero e para prevenir ou tratar doenças circulatórias em um mamìfero, e, uso do composto
BR9908610A (pt) Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto, processos par ainibir a produção de óxido nìtrico e/ou citocina em mamìferos, e para impedir ou tratar doença cardìaca, doença autoimune ou choque séptico em mamìferos, e, pró medicamentos
MX2009011755A (es) Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas.
BR0215622A (pt) Inibidores da dpiv com base em glutaminila
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
NO20054876L (no) Substituerte 4-fenyltetrahydroisokinoliner, fremgangsmate for fremstilling derav, deres anvendelse som medikament og medikament inneholdende slike forbindelser
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0517621A (pt) sais hidroxibenzoato de compostos de metanicotina
CY1109569T1 (el) Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
MXPA06000701A (es) Compuestos de sulfonildihidrobencimidazolona como ligandos de 5-hidroxitriptamina-6.
UA99492C2 (ru) Производные 1,3-дигидро-5-изобензофуранкарбонитрила и его фармацевтическая композиция для лечения преждевременной эякуляции
MY158069A (en) Tricyclic compound and pharmaceutical use thereof
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
DE50007381D1 (de) Verwendung von polyzyklischen thiazol-systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas
EA201000832A1 (ru) Замещённые 3-гидроксипиридины и содержащие их фармацевтические композиции
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
MXPA05010165A (es) Derivados de prolina biciclicos [c]-condensados y su uso para el tratamiento de estados artriticos.
MY136965A (en) 1,4-disubstituted piperidine compounds, their preparation and use as medicaments
MXPA05011168A (es) Derivados de prolina biciclicos [b]-condensados y sus usos para tratar afecciones artriticas.
RU94033470A (ru) Циклогексановые производные, фармкомпозиция на их основе и способ лечения

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.